Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors
Clinical Pharmacology & Therapeutics · 2025-01 · 117 (1) · 56-72
DOI: 10.1002/cpt.3398 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 15.08.2024. Verfasst von Jessie P Bakker und 6 weiteren Autor:innen. Beteiligte Einrichtung: Koneksa Health, New York, New York, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Endpoint Determination. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Digitalisierung in der Pflege
Abstract (Originalsprache)
Despite widespread interest and substantial investment in the adoption of sensor‐based digital health technologies (sDHTs) for remote data capture in drug development trials, no drug has been approved based on an sDHT‐derived primary endpoint in the United States (US). One reason for this lack of advancement is the complexity of obtaining regulatory endorsement for those endpoints within current US regulatory pathways. The goal of our review is to describe the two choices currently available to pharmaceutical study Sponsors: (i) they may navigate the traditional route of compiling the evidence to support the sDHT‐derived endpoint in their investigational new drug (IND) application, requiring specific expertise and substantial resources; or (ii) they may navigate the drug development tool (DDT) pathway with the goal of qualifying their sDHT‐derived endpoint as a biomarker or clinical outcome assessment applicable to a broader context of use (COU), either alone or as part of a partnership or consortium. We describe the nuances of each pathway; the evidentiary requirements for supporting an sDHT‐derived endpoint and the technology used to capture it; and the impact that an sDHT's regulatory status may have on a Sponsor's decision to use it for data capture. By systematically comparing the IND and DDT pathways, our over‐arching goals are to support the increasing deployment of sDHTs within the clinical research setting and help advance regulatory science in the field of digital medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Koneksa Health, New York, New York, USA.
- F.Hoffmann-La Roche Ltd, Basel, Switzerland.
- Science Partnerships, Foundation for the National Institutes of Health, North Bethesda, Maryland, USA.
- Greenleaf Health, Washington, District of Columbia, USA.
ORCID-Profile: Elena S Izmailova
Zitieren
APA
Bakker, J. P., Izmailova, E. S., Clement, A., Hoffmann, S., Leptak, C., Menetski, J. P., & Wagner, J. A. (2025). Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors. Clinical Pharmacology & Therapeutics, 117(1), 56-72. https://doi.org/10.1002/cpt.3398
Vancouver
Bakker JP, Izmailova ES, Clement A, Hoffmann S, Leptak C, Menetski JP, et al. Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors. Clinical Pharmacology & Therapeutics. 2025;117(1):56-72. doi:10.1002/cpt.3398
BibTeX
@article{Bakker2025,
author = {Bakker, Jessie P and Izmailova, Elena S and Clement, Aude and Hoffmann, Steven and Leptak, Christopher and Menetski, Joseph P and Wagner, John A},
title = {Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {117},
number = {1},
pages = {56--72},
doi = {10.1002/cpt.3398}
}
EUVIMED